Please assess the completion status of the following clinical trial:

Trial Title: Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must be diagnosed as hematopoiesis disorders and receiving hematopoietic stem cells transplantation.~2. Steroid dependent or refractory classic chronic GVHD disease defined as modified National Institutes of Health criteria(2014) below at any time post-hematopoietic cell transplant(post-HCT)~   1. Dependent disease, defined as, when glucocorticoid (prednisolone doses greater than or equal to(\<=) 0.25mg/kg/day or \<=0.5mg/kg every other day(prednisolone doses) due to recurrence or progression of cGVHD manifestations, it is considered as steroid-dependent disease if the lowest tapering dose of the second occasion is equal or higher than the lowest tapering dose of the first occasion~  2. Refractory disease, defined as, when cGVHD manifestations progress despite the use of a regime containing glucocorticoid (prednisolone at \>=1mg/kg/day for at least 1 week) or persist without improvement despite continued treatment with glucocorticoid (prednisolone at \>=0.5mg/kg/day or 1mg/kg every other day) for at least 4 weeks.~3. Participants must be receiving baseline systemic glucocorticoid therpy for cGVHD at study entry. The dose of steroids must be stable for 14 days prior to starting anlotinib.~4. At the time of trial enrollment, participants may be receiving other immunosuppressive therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for 14 days prior to starting anlotinib.~5. Neutrophil≥1.5×109/L，platelet≥50×109/L~6. Karnofsky or Lansky performance status\>=60~7. Participants should sign the agreement.~Exclusion Criteria:~1. Known or suspected active acute GVHD.~2. Current treatment with a tyrosine kinase inhibitor, purin analogs or other cancer chemotherapy in the 4weeks prior to starting study drug.~3. Concomitant use of warfarin or other Vitamin K antogonists.~4. Known bleeding disorders or hemophilia.~5. Known history of human immunodeficiency virus or active with hepatitis C. virus or hepatitis B virus.~6. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicine or recent infection requiring systemic treatment .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- therapy (Type: EXPERIMENTAL): therapy with 1 arm. Anlotinib 8mg qd po。

Based on this trial design, predict the completion outcome and termination type (if applicable).